Ore Holdings Inc. (fka ORXE)

[Renee]

ORXE: Shareholders will received $0.20 for each share of ORXE held.

FINRA deleted symbol:

http://otce.finra.org/DLDeletions

[surf1944]

Still just waiting to see if Steel Partners can do anything with ORXE, current price of .40, hopefully could work out to be $1 or $2 dollars at some point..

[surf1944]

Still just waiting to see if Steel Partners can do anything with ORXE, current price of .30, hopefully could work out to be $1 or $2 dollars at some point....

[surf1944]

Still just waiting to see if Steel Partners can do anything with ORXE, current price of .20, hopefully could work out to be $1 or $2 dollars at some point....

[surf1944]

Steel partners has done this with other companies that it owned or had more than a 51% stake in the company. I talked with Jack Howard a couple of times this year & he is actively searching for a buyer or partnership to increase the value of their holdings in the stock. In one conversation he discussed the large number of shareholders that had less than a couple thousand shares, anyone with less than 10k is now gone. I am giving it another 6-12 months to see if they can move it to a dollar.

surf

[Stock]

no bid or ask since reverse split/forward split.

is the transfer agent really in charge of selling odd lots for shareholders that had less than 10,000 shares?

weird.

-------

6/13/2011 ORXE 1-10,000 R/S immediately followed by 10,000-1 F/S;

Ore Pharmaceutical Holdings Inc. 1-10,000 R/S immediately followed by 10,000-1 F/S; Whereby Transfer Agent shall aggregate all such fractional shares and sell them as soon as practicable at the then prevailing prices on the open market, on behalf of those stockholders who would otherwise be entitled to receive a fractional share. After the Transfer Agent's completion of such sale, stockholders shall receive a cash payment from the transfer agent in an amount equal to their respective pro rate shares of the total net proceeds of that sale.

New Symbol ORXED - Ore Holdings Inc.

[Renee]

ORXE : One for 10,000 R/S followed by 10,000 for one Forward split .

http://www.otcbb.com/asp/dailylist_detail.asp?d=06/10/2011&mkt_ctg=OTCBB

[surf1944]

http://www.form4oracle.com/company/ore-pharmaceutical-holdings-inc-orxe/company-transactions?id=967

[surf1944]

ORXE should have a Bullish 50/200-day MA Crossover next week....

[surf1944]

chart breakout may be coming for ORXE on some good volume......

[BogeyMan]

Will be watching this one.

[surf1944]

Sillerman buys shell, shares soar 25,000%

By GARETT SLOANE

Last Updated: 1:42 AM, February 9, 2011

Posted: 12:23 AM, February 9, 2011
Comments: 0
More Print

The founder of the company which owns "American Idol" has just taken another no-name to new heights.

Robert F.X. Sillerman took control of dormant public company Gateway Industries yesterday and sent its stock soaring from about 2 cents a share to nearly $3 after he said the company would be the launching pad for a new venture.

That's a 25,000 percent gain.

The deal for Gateway, whose sole employee is CEO Jack Howard, gives Sillerman and other investors a 98 percent stake in the company after they bought 120 million shares at 3 cents each, for a total of $3.6 million.

The newly constituted company will be called Function (X), but Sillerman is being coy about what his next move will be.

Gateway's shares closed yesterday at $1.89 after giving back a third of their gains in the afternoon. Gateway had no revenue last year and a total of $5 on hand.

Reps for Sillerman said he would not have further comments. Howard did not return calls.

Sillerman, 62, is best known for being the CEO of CKX when that company bought 19 Entertainment, the firm that developed "American Idol." Sillerman, a native New Yorker, is considered to have the golden touch in the entertainment industry.

He sold his concert promotion company SFX Entertainment to Clear Channel Communications for $4 billion in 2000.

Five years later, he orchestrated the deal to buy Entertainment 19 for a steal: $160 million.

Read more: http://www.nypost.com/p/news/business/sillerman_buys_shell_shares_soar_iR6IbzjJC0Qv1Blx09qUHN#ixzz1F7KvOtq2


http://blogs.wsj.com/deals/2011/02/08/american-idol-backer-robert-sillerman-launches-new-media-venture/

[surf1944]

Ore Pharmaceutical Holdings Inc. Announces $5.3 Million Investment by Steel Partners

ORXE should move up when the volume kicks in

Press Release Source: Ore Pharmaceutical Holdings Inc. On Friday October 22, 2010, 4:30 pm EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ore Pharmaceutical Holdings Inc. (OTC:ORXE.PK.ob - News), announced today that Steel Partners, Ltd. has completed a $5.3 million combined debt and equity investment in the Company. The investment is composed of an equity investment of $1.1 million (3,125,000 newly issued Common Shares priced at $0.35 per share) and a note with a five year maturity for $4.2 million. As part of the transaction, Steel has been provided with the right to nominate two new directors to the Company to replace two current directors, who have resigned in conjunction with the transaction.

“We are very excited about this transaction,” said J. Stark Thompson, PhD, Chairman of the Ore Board of Directors. “This investment by Steel provides significant capital for Ore to put to work as it pursues new opportunities to acquire profitable businesses that can operate under the Ore umbrella. I look forward to working with the new Board of Directors and Steel Partners to implement this strategy and find new ways to create value for Ore shareholders.” As part of the transaction, Jack Howard, one of the new Steel directors, will become Chairman of the Board.

p-Value Capital Management, LLC, a specialized healthcare asset management firm, has been managing Ore under a management services agreement, including providing Ore with its senior executive team. In conjunction with this transaction and the new corporate strategy, p-Value will terminate its current management agreement. p-Value will continue to work with the Company on a consulting basis to assist the new Ore Board with the ongoing clinical trial of its lead development-stage pharmaceutical product ORE-1001, as well as other operating activities.

As previously disclosed, Ore has suspended its SEC registration and no longer provides financial or other information through SEC filings. Ore intends to continue providing quarterly and financial information about the company on its web site, www.orepharma.com, as well as through other distribution methods it may identify, and to stockholders directly upon written request.

Ore Pharmaceutical Holdings Overview

Ore Pharmaceutical Holdings Inc. (the “Company”) is currently focused on developing and monetizing its current portfolio of pharmaceutical assets, which includes four clinical-stage compounds in-licensed from major pharmaceutical companies: ORE1001, its lead compound, ORE10002, ORE5002 (tiapamil) and ORE5007 (romazarit).

[surf1944]

http://investing.businessweek.com/businessweek/research/stocks/private/person.asp?personId=300995&privcapId=300991&previousCapId=24296&previousTitle=Adaptec%20Inc.

http://people.forbes.com/profile/jack-l-howard/1264

http://www.hedgetracker.com/fund.php?id=20&s=10&p=3

[mlkrborn]

0.39 now with 4k volume?

[surf1944]

ORXE is breaking out on the charts, but the problem is no volume. The next surge of volume will indicate the direction for ORXE & I am positioned for the upside breakout.


http://www.barchart.com/quotes/stocks/ORXE

[surf1944]

These guys don't place monies into a stock to lose it. They have a good track record, but the only problem is the stock is so thin. On the the other hand if it does have some great news in the coming months, I'll be able to help control the rise in the stock price.

[mlkrborn]

It seems MRNA purchased assets of ORXE not long ago.
"MRNA acquiring ORXE assets pipeline/cash and not the Liabilities of the company.

The benefit combining the three companies could be (a)staying in business longer (b)inturn bringing componds to the bigger guys.

The benefit to ORXE stock holders might be we would recieve MRNA shares and may be a quicker way to complete ORE1001 phase II. "
source: YMB

[mlkrborn]

CAMBRIDGE, Mass., Oct 22, 2010 (BUSINESS WIRE) -- Ore Pharmaceutical Holdings Inc. (OTC: ORXE.PK), announced today that Steel Partners, Ltd. has completed a $5.3 million combined debt and equity investment in the Company. The investment is composed of an equity investment of $1.1 million (3,125,000 newly issued Common Shares priced at $0.35 per share) and a note with a five year maturity for $4.2 million. As part of the transaction, Steel has been provided with the right to nominate two new directors to the Company to replace two current directors, who have resigned in conjunction with the transaction.
"We are very excited about this transaction," said J. Stark Thompson, PhD, Chairman of the Ore Board of Directors. "This investment by Steel provides significant capital for Ore to put to work as it pursues new opportunities to acquire profitable businesses that can operate under the Ore umbrella. I look forward to working with the new Board of Directors and Steel Partners to implement this strategy and find new ways to create value for Ore shareholders." As part of the transaction, Jack Howard, one of the new Steel directors, will become Chairman of the Board.

p-Value Capital Management, LLC, a specialized healthcare asset management firm, has been managing Ore under a management services agreement, including providing Ore with its senior executive team. In conjunction with this transaction and the new corporate strategy, p-Value will terminate its current management agreement. p-Value will continue to work with the Company on a consulting basis to assist the new Ore Board with the ongoing clinical trial of its lead development-stage pharmaceutical product ORE-1001, as well as other operating activities.

As previously disclosed, Ore has suspended its SEC registration and no longer provides financial or other information through SEC filings. Ore intends to continue providing quarterly and financial information about the company on its web site, www.orepharma.com, as well as through other distribution methods it may identify, and to stockholders directly upon written request.

[mlkrborn]

multi-years chart!
http://finance.yahoo.com/echarts?s=ORXE.PK+Interactive#chart1:symbol=orxe.pk;range=my;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined

[mlkrborn]

sept 2010 report:
Ore Pharmaceutical Holdings Inc. Announces Financial Results for the Quarter Ended September 30, 2010
Ore Pharmaceuticals (USOTC:ORXE)
Historical Stock Chart

3 Months : October 2010 to January 2011
Click Here for more Ore Pharmaceuticals Charts.

Ore Pharmaceutical Holdings Inc. (OTC: ORXE.PK), today announced its financial results for the three month and nine month periods ended September 30, 2010. Net loss for the three months ended September 30, 2010 was $237,000, or $0.04 per share, as compared to a net loss of $594,000 or $0.11 per share for the three months ended September 30, 2009. There was no revenue for the three month periods ended September 30, 2010 or 2009, respectively. Net loss for the nine months ended September 30, 2010 was $2,307,000 or $0.42 per share, as compared to a net loss of $6,287,000 or $1.15 per share for the nine months ended September 30, 2009. There was no revenue for the nine months ended September 30, 2010 and $25,000 in revenue for the nine months ended September 30, 2009.

As previously reported, Ore has suspended its SEC registration and no longer provides financial or other information through SEC filings. Ore intends to continue to provide quarterly and annual financial information by posting such information on its web site, www.orepharma.com.

Ore Pharmaceutical Holdings Overview

Ore Pharmaceutical Holdings Inc. is currently focused on developing and monetizing its current portfolio of pharmaceutical assets, which includes four clinical stage compounds in-licensed from major pharmaceutical companies.

[mlkrborn]

Surf; Good lead! ADPT and SLI are two other purchases which i dont know anything about. They paid 0.35 for ORXE in their recent investment. This must be base for a while i assume..
GL
Great to see you getting active again.

[surf1944]

http://stockpickr.com/pro/portfolio/steel-partners/

http://www.secform4.com/insider-trading/1005784.htm

More research on Steel Partners, all of the investment positions have gone up since their purchases.....

[surf1944]

bought over a 100k shares in the past few weeks on weakness below .30, with this being thin and a pink now, any good news on progress and up 100%, on real news over $1, on great news it will go as far as Steel wants it to go.....

[surf1944]

http://www.nasdaq.com/asp/quotes_sec.asp?symbol=orxe&selected=orxe

[surf1944]

http://www.form4oracle.com/company/ore-pharmaceutical-holdings-inc-orxe/company-transactions?id=967

[mlkrborn]

SURF ! great to see you surfacing again.. Your absence is strongly felt in 130 plus boards you worked so hard..

[dragonball]

surf,

why did you gave up all the mods join.

you were one of the biotech kings?

what happen.

can you PM this pirate why?????

AARGG!

[surf1944]

http://www.secform4.com/insider-trading/1043914.htm

[surf1944]

Ore Pharmaceutical Holdings Inc. Announces $5.3 Million Investment by Steel Partners

ORXE should move up when the volume kicks in

Press Release Source: Ore Pharmaceutical Holdings Inc. On Friday October 22, 2010, 4:30 pm EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ore Pharmaceutical Holdings Inc. (OTC:ORXE.PK.ob - News), announced today that Steel Partners, Ltd. has completed a $5.3 million combined debt and equity investment in the Company. The investment is composed of an equity investment of $1.1 million (3,125,000 newly issued Common Shares priced at $0.35 per share) and a note with a five year maturity for $4.2 million. As part of the transaction, Steel has been provided with the right to nominate two new directors to the Company to replace two current directors, who have resigned in conjunction with the transaction.

“We are very excited about this transaction,” said J. Stark Thompson, PhD, Chairman of the Ore Board of Directors. “This investment by Steel provides significant capital for Ore to put to work as it pursues new opportunities to acquire profitable businesses that can operate under the Ore umbrella. I look forward to working with the new Board of Directors and Steel Partners to implement this strategy and find new ways to create value for Ore shareholders.” As part of the transaction, Jack Howard, one of the new Steel directors, will become Chairman of the Board.

p-Value Capital Management, LLC, a specialized healthcare asset management firm, has been managing Ore under a management services agreement, including providing Ore with its senior executive team. In conjunction with this transaction and the new corporate strategy, p-Value will terminate its current management agreement. p-Value will continue to work with the Company on a consulting basis to assist the new Ore Board with the ongoing clinical trial of its lead development-stage pharmaceutical product ORE-1001, as well as other operating activities.

As previously disclosed, Ore has suspended its SEC registration and no longer provides financial or other information through SEC filings. Ore intends to continue providing quarterly and financial information about the company on its web site, www.orepharma.com, as well as through other distribution methods it may identify, and to stockholders directly upon written request.

Ore Pharmaceutical Holdings Overview

Ore Pharmaceutical Holdings Inc. (the “Company”) is currently focused on developing and monetizing its current portfolio of pharmaceutical assets, which includes four clinical-stage compounds in-licensed from major pharmaceutical companies: ORE1001, its lead compound, ORE10002, ORE5002 (tiapamil) and ORE5007 (romazarit).

[Stock]

.37

[hm36tm]

I wonder how many buy orders in the $0.45 area, when tomorrow the stock will be delisted from Nasdaq...

[surf1944]

ORXE qtr report to be out by 3/15 & just saw a 92k buy order on L2, have no idea which way it goes.....

[hm36tm]

86,700 shares for sale @$0.86 and nobody is buying...

[surf1944]

May be some volume action in ORXE today, first time in a while that a large seller has shown itself. There is a 30k buy order hidden in the bids, we'll see if it comes up to the ask & takes it, it was doing that a couple of weeks ago....

[surf1944]

If ORXE releases any news that is at least a little interesting the stock will fly, the bar for the company is so low it is setting on the ground.........

[Stock]

thx. still holding and hopeful. perhaps too much so, but i'm guilty as charged lol

[surf1944]

The qtr report will be out prior to 3/15, if there is any any news we will know in the next 2 or 3 weeks.....

[Stock]

something is up, gut feeling watching L2, different...

[surf1944]

My shares are set to sell at $3, they aren't showing up yet! Keeping them off the market so they can't be loaned out for shorting................

[Stock]

GSCO ask is 1.39 but I don't see them on the bid

wink wink

[Stock]

thanks for the info.

[surf1944]

Everytime a big seller has shown an order over the past couple of weeks they have stepped up the ask and taken the stock. The days it has dropped have been on little to no volume & the up days on large volume, at least for ORXE it is big volume. I have no idea why the current interest in the stock, I called the company & the only item I could get was that the qtr report 10K would be out by 3/15/2010.

[Stock]

5,473,519 and 5,483,519 shares issued and outstanding as of September 30, 2009 and December 31, 2008

[surf1944]

ORXE will hit the new 52 week high list tonight, about time this puppydog started to shake its fleas...........

[surf1944]

Finally the orders are coming for ORXE, just saw a 60k bid hit the tape above the offering..............

[Stock]

I'm ready for that.

[surf1944]

Just noticed that ORXE has the strongest bid building/support since the last run. May have a big run here soon along with all these other small cap biotech stocks.

surf

[surf1944]

I believe 2010 has to be the year for ORXE to have a parabolic spike & if doesn't it will be near to its last year as a going concern.

surf

[Stock]

Get a win in 2010